This study will test the safety and effectiveness of a new drug, barzolvolimab, in treating adults with Atopic Dermatitis (AD), a chronic skin condition causing itchy, inflamed skin. The study is **double-blind**, meaning neither the participants nor the doctors know who is receiving the actual drug or a **placebo** (a harmless pill with no treatment effect). It lasts for about **48 weeks** and includes several phases: a 28-day screening, a 16-week treatment with either the drug or placebo, another 16-week treatment phase, and a 16-week follow-up period. Participants will receive the drug through injections every four weeks. To be a part of this study, you must be 18 years or older, have had AD for over a year, and experienced moderate to severe symptoms. You should also be willing to keep a daily electronic diary of your symptoms.

• The study lasts for about 48 weeks.
• Participants receive injections every 4 weeks.
• Must be able to keep a daily symptom diary.